Notice NOT-AA-17-009 from the NIH Guide for Grants and Contracts

Notice NOT-RM-17-036 from the NIH Guide for Grants and Contracts

Notice NOT-DA-17-052 from the NIH Guide for Grants and Contracts

Notice NOT-AA-17-011 from the NIH Guide for Grants and Contracts

Notice NOT-EB-17-009 from the NIH Guide for Grants and Contracts

Notice NOT-HD-17-019 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-RM-17-029 from the NIH Guide for Grants and Contracts. The Common Fund Program - Accelerating Translation of Glycoscience: Integration and Accessibility - aims to develop accessible and affordable new tools and technologies for studying carbohydrates that will allow biomedical researchers to significantly advance our understanding of the roles of these complex molecules in health and disease. This program will enable investigators who might not otherwise conduct research in the glycosciences, to undertake the study of carbohydrate structure and function.

Funding Opportunity RFA-RM-17-030 from the NIH Guide for Grants and Contracts. The Common Fund Program - Accelerating Translation of Glycoscience: Integration and Accessibility - aims to develop accessible and affordable new tools and technologies for studying carbohydrates that will allow biomedical researchers to significantly advance our understanding of the roles of these complex molecules in health and disease. This program will enable investigators who might not otherwise conduct research in the glycosciences, to undertake the study of carbohydrate structure and function.

Funding Opportunity PA-17-449 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate research in the interplay between cell death pathways in nave and drug resistant cancers. Regulated cell death, especially apoptosis and necroptosis, are natural barriers that restrict malignant cells from surviving and disseminating. Evasion of cell death mechanisms is one of the hallmarks of cancer contributing to tumor progression, metastases and resistance to therapy. Recent studies show that the machinery to activate different forms of cell death coexists in cells but the crosstalk of cell death pathways in cancer has not been systematically studied. Research into the intersection of cell death programs will allow for better defining markers of cell death pathway at the molecular level and offers the possibility that the specific mediators of cell survival may be inhibited and/or the mediators of cell death enhanced, driving nave and drug resistant cancer cells toward effective cell death.

Funding Opportunity PA-17-440 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate research in the interplay between cell death pathways in nave and drug resistant cancers. Regulated cell death, especially apoptosis and necroptosis, are natural barriers that restrict malignant cells from surviving and disseminating. Evasion of cell death mechanisms is one of the hallmarks of cancer contributing to tumor progression, metastases and resistance to therapy. Recent studies show that the machinery to activate different forms of cell death coexists in cells but the crosstalk of cell death pathways in cancer has not been systematically studied. Research into the intersection of cell death programs will allow for better defining markers of cell death pathway at the molecular level and offers the possibility that the specific mediators of cell survival may be inhibited and/or the mediators of cell death enhanced, driving nave and drug resistant cancer cells toward effective cell death.

Funding Opportunity PAR-17-441 from the NIH Guide for Grants and Contracts. This FOA will support exploratory/developmental research programs of interest to the NIBIB (https://www.nibib.nih.gov/research-funding). These studies are expected to lead to breakthroughs in development of innovative techniques, agents, methodologies, models, or their applications. These studies may involve considerable risk that should be balanced by the potential high impact on human-health and related research. Applicants are expected to propose novel biomedical research approaches for which there is no preliminary data to demonstrate the feasibility of the proposed project. A project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven.

Notice NOT-EB-17-008 from the NIH Guide for Grants and Contracts

Notice NOT-EB-17-007 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-17-049 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research on fusion oncoproteins in childhood cancers. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation E. Intensify research on the major drivers of childhood cancers: Improve our understanding of fusion oncoproteins in pediatric cancer and use new preclinical models to develop inhibitors that target them. The goal of this FOA is to establish a consortium of collaborating research teams to advance our understanding of the biology and mechanisms of action of fusion oncoproteins in pediatric cancers, and to apply this knowledge towards developing targeted therapeutic approaches. Increased attention to this important but understudied field can help overcome existing barriers to progress and pave the way to novel therapeutic approaches with increased efficacy and fewer side effects than current options. The research teams comprising the Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium will take a comprehensive approach to understanding the biology of fusion oncoproteins in childhood cancers and will use this information to inform strategies for therapeutic targeting.

Notice NOT-OD-17-097 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-18-015 from the NIH Guide for Grants and Contracts. The purpose of this RFA is to promote research investigating the underlying mechanisms by which opioids including prescription drugs exacerbate HIV-associated neuropathic pain. Results from these studies may help obtain information for developing safe and effective treatments of neuropathic pain for HIV-infected patients exposed to opioids.

Funding Opportunity RFA-DA-18-014 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity is to identify genetic and epigenetic factors that affect the recovery of the CD4+ T cells in response to anti-retroviral therapy in HIV infected people who inject drugs infected

Notice NOT-HG-17-012 from the NIH Guide for Grants and Contracts

Notice NOT-AI-17-033 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-17-452 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) issued by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) encourages research project grants (R01) investigating the incidence, course, and outcomes of pregnancy among women with disabilities. Areas of interest also include studies to inform preconceptional and antenatal counseling and strategies for addressing barriers to prenatal care, and management of pregnancy, the puerperium, and the transition to parenthood in order to optimize outcomes for women with physical, intellectual and developmental, and/or sensory disabilities and their families. Applicants are encouraged to include women with disabilities and members of the community in the design and conduct of their research.